Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors

4 Aug 2016

Abstract excerpt

IMPORTANCE: Checkpoint blockade therapy targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathways (PD-1/PD-L1) have achieved success in treating a number of malignancies. However, only a subset of patients responds to these therapies, and optimization of patient selection for treatment is imperative to avoid adverse effects without clinical benefit and keep...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Ferroptosis and cancer prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27491050
DOI: 10.1001/jamaoncol.2016.2214

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint InhibitorsPMID 27491050Read ↗

Genomics of response to immune checkpoint therapies for cancer: implications for precision medicineSemantic proximity Read ↗

A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade ImmunotherapySemantic proximity Read ↗

Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor ImmunotherapySemantic proximity Read ↗

Immune checkpoints and cancer in the immunogenomics eraSemantic proximity Read ↗

Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in CancerSemantic proximity Read ↗

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.Semantic proximity Read ↗

Genomics-Guided Immunotherapy for Precision Medicine in CancerSemantic proximity Read ↗

Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockadeSemantic proximity Read ↗

Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy.Semantic proximity Read ↗

Advances and prospects of biomarkers for immune checkpoint inhibitorsSemantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.